Carla R Schubert1, Mary E Fischer2, A Alex Pinto2, Adam J Paulsen2, Yanjun Chen2, Guan-Hua Huang3, Barbara E K Klein2, Michael Y Tsai4, Natascha Merten5,6,7, Karen J Cruickshanks2,5. 1. Department of Ophthalmology and Visual Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Rm 1087 WARF, 610 Walnut Street, Madison, WI, 53726, USA. schubert@episense.wisc.edu. 2. Department of Ophthalmology and Visual Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Rm 1087 WARF, 610 Walnut Street, Madison, WI, 53726, USA. 3. Institute of Statistics, National Yang Ming Chiao Tung University, 1001 University Road, Hsinchu, 30010, Taiwan. 4. Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware Street S.E, Minneapolis, MN, 55455, USA. 5. Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, 610 Walnut Street, Madison, WI, 53726, USA. 6. Division of Geriatrics and Gerontology, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA. 7. Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Abstract
BACKGROUND: Age-related declines in cognitive function may begin in midlife. PURPOSE: To determine whether blood-based biomarkers of inflammation, metabolic dysregulation and neurotoxins are associated with risk of cognitive decline and impairment. METHODS: Baseline blood samples from the longitudinal Beaver Dam Offspring Study (2005-2008) were assayed for markers of inflammation, metabolic dysregulation, and environmental neurotoxins. Cognitive function was measured at baseline, 5-year (2010-2013) and 10-year (2015-2017) examinations. Participants without cognitive impairment at baseline and with cognitive data from at least one follow-up were included. Cox proportional hazards models were used to evaluate associations between baseline blood biomarkers and the 10-year cumulative incidence of cognitive impairment. Poisson models were used to estimate the relative risk (RR) of 5-year decline in cognitive function by baseline blood biomarkers. Models were adjusted for age, sex, education, and cardiovascular related risk factors. RESULTS: Participants (N = 2421) were a mean age of 49 years and 55% were women. Soluble vascular cell adhesion molecule-1 (sVCAM-1Tertile(T)3 vs T1-2 hazard ratio (HR) = 1.72, 95% confidence interval (CI) = 1.05,2.82) and hemoglobin A1C (HR = 1.75, 95% CI = 1.18,2.59, per 1% in women) were associated with the 10-year cumulative incidence of cognitive impairment. sVCAM-1 (RRT3 vs T1-2 = 1.45, 95% CI = 1.06,1.99) and white blood cell count (RR = 1.10, 95% CI = 1.02,1.19, per 103/μL) were associated with 5-year cognitive decline. CONCLUSIONS: Biomarkers related to inflammation and metabolic dysregulation were associated with an increased risk of developing cognitive decline and impairment. These results extend previous research in cognitive aging to early markers of cognitive decline in midlife, a time when intervention methods may be more efficacious.
BACKGROUND: Age-related declines in cognitive function may begin in midlife. PURPOSE: To determine whether blood-based biomarkers of inflammation, metabolic dysregulation and neurotoxins are associated with risk of cognitive decline and impairment. METHODS: Baseline blood samples from the longitudinal Beaver Dam Offspring Study (2005-2008) were assayed for markers of inflammation, metabolic dysregulation, and environmental neurotoxins. Cognitive function was measured at baseline, 5-year (2010-2013) and 10-year (2015-2017) examinations. Participants without cognitive impairment at baseline and with cognitive data from at least one follow-up were included. Cox proportional hazards models were used to evaluate associations between baseline blood biomarkers and the 10-year cumulative incidence of cognitive impairment. Poisson models were used to estimate the relative risk (RR) of 5-year decline in cognitive function by baseline blood biomarkers. Models were adjusted for age, sex, education, and cardiovascular related risk factors. RESULTS: Participants (N = 2421) were a mean age of 49 years and 55% were women. Soluble vascular cell adhesion molecule-1 (sVCAM-1Tertile(T)3 vs T1-2 hazard ratio (HR) = 1.72, 95% confidence interval (CI) = 1.05,2.82) and hemoglobin A1C (HR = 1.75, 95% CI = 1.18,2.59, per 1% in women) were associated with the 10-year cumulative incidence of cognitive impairment. sVCAM-1 (RRT3 vs T1-2 = 1.45, 95% CI = 1.06,1.99) and white blood cell count (RR = 1.10, 95% CI = 1.02,1.19, per 103/μL) were associated with 5-year cognitive decline. CONCLUSIONS: Biomarkers related to inflammation and metabolic dysregulation were associated with an increased risk of developing cognitive decline and impairment. These results extend previous research in cognitive aging to early markers of cognitive decline in midlife, a time when intervention methods may be more efficacious.
Authors: Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Margarete A Wichmann; Karen J Cruickshanks; Cynthia M Carlsson; Rick Chappell; Mary E Fischer; Barbara E K Klein; Ronald Klein; Michael Y Tsai; Carla R Schubert Journal: J Am Geriatr Soc Date: 2014-08-14 Impact factor: 5.562
Authors: Alan Rembach; Andrew D Watt; William J Wilson; Stephanie Rainey-Smith; Kathryn A Ellis; Christopher C Rowe; Victor L Villemagne; S Lance Macaulay; Ashley I Bush; Ralph N Martins; David Ames; Colin L Masters; James D Doecke Journal: J Neuroimmunol Date: 2014-05-20 Impact factor: 3.478
Authors: Kristen N Warren; Lori L Beason-Held; Olga Carlson; Josephine M Egan; Yang An; Jimit Doshi; Christos Davatzikos; Luigi Ferrucci; Susan M Resnick Journal: J Gerontol A Biol Sci Med Sci Date: 2018-05-09 Impact factor: 6.053
Authors: Yian Gu; Robert Vorburger; Nikolaos Scarmeas; José A Luchsinger; Jennifer J Manly; Nicole Schupf; Richard Mayeux; Adam M Brickman Journal: Brain Behav Immun Date: 2017-04-27 Impact factor: 7.217
Authors: Marianne J Engelhart; Mirjam I Geerlings; John Meijer; Amanda Kiliaan; Annemieke Ruitenberg; John C van Swieten; Theo Stijnen; Albert Hofman; Jacqueline C M Witteman; Monique M B Breteler Journal: Arch Neurol Date: 2004-05
Authors: Keenan A Walker; Rebecca F Gottesman; Aozhou Wu; David S Knopman; Alden L Gross; Thomas H Mosley; Elizabeth Selvin; B Gwen Windham Journal: Neurology Date: 2019-02-13 Impact factor: 9.910
Authors: Kimberly D van der Willik; Lana Fani; Dimitris Rizopoulos; Silvan Licher; Jesse Fest; Sanne B Schagen; M Kamran Ikram; M Arfan Ikram Journal: J Neuroinflammation Date: 2019-03-30 Impact factor: 8.322